Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XB628 as a Single Agent and in Combination With Zanzalintinib in Advanced or Metastatic Solid Tumors
NCT06952010Phase 1Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of XB628 in solid tumor (2 arms), sponsored by Exelixis, Inc. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment Emergent Adverse Events at 27 months and 1 more. Started May 2025; status: recruiting.
02
Drugs
XB628
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06952010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952010.